Bank of Montreal
KPTI icon

Bank of Montreal’s Karyopharm Therapeutics KPTI Stock Holding History

Bank of Montreal’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-567
Closed -$160K – 4853
2020
Q2 		$160K Buy
+567
New +$168K ﹤0.01% 2846

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of Montreal's KPTI Position: Q3 2021 in Review

Bank of Montreal sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 36 shares — an estimated $6K sold.

Bank of Montreal first reported a position in KPTI in Q2 2014 and held it in 22 quarters. The position peaked at $210K in Q1 2017. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Bank of Montreal reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Bank of Montreal sold 36 Karyopharm Therapeutics shares in Q3 2021, an estimated $6K.
  • Bank of Montreal first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 22 quarters.
  • Bank of Montreal's Karyopharm Therapeutics position peaked at $210K in Q1 2017.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Bank of Montreal's 13F filing for Q3 2021, filed 12 Nov 2021.